Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
| Revenue (TTM) | $3.77B |
| Gross Profit (TTM) | $2.08B |
| EBITDA | $1.14B |
| Operating Margin | 2.84% |
| Return on Equity | 5.21% |
| Return on Assets | 3.31% |
| Revenue/Share (TTM) | $57.84 |
| Book Value | $155.78 |
| Price-to-Book | 2.38 |
| Price-to-Sales (TTM) | 10.00 |
| EV/Revenue | 11.02 |
| EV/EBITDA | 41.95 |
| Quarterly Earnings Growth (YoY) | -3.10% |
| Quarterly Revenue Growth (YoY) | 91.40% |
| Shares Outstanding | $98.19M |
| Float | $98.00M |
| % Insiders | 0.10% |
| % Institutions | 100.00% |
Volatility is currently expanding
Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Waters (WAT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Brings Xevo™ TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, cancer assessment, and toxicology. Offers 5x greater sensitivity vs.
Waters Corporation remains a Hold as valuation concerns are balanced by ongoing synergy capture from its Becton, Dickinson acquisition. WAT's Q1 pro forma sales rose to $1.54B, with legacy revenue up 13% and recurring revenue surging 123%, signaling broad-based growth. Synergy realization is on track, with $55M+ cost savings and $50M revenue synergies targeted for 2026, supporting incremental EBITDA gains.
MILFORD, Mass., July 2, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q2 2026 financial results conference call on Tuesday, August 4, 2026, at 8:00 a.m.
Integrates heat flow, evolved gas, and electrochemical analysis in a single experiment, enabling earlier insights into thermal runaway. Unique whole-cell design eliminates cell teardown, reducing sample preparation time by >90%.
Waters (WAT) reported earnings 30 days ago. What's next for the stock?
Waters Corporation (WAT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics. Achieves a 3-hour faster time to detection (~15% reduction) versus the prior-generation system, per clinical study data, enabling earlier targeted sepsis prevention.
Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows. Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research and disease understanding.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on WAT and any ticker you trade — then tracks every position and per-strategy win rate.
